Immunovant, Inc. (IMVT) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. My name is Melissa, and I will serve as your conference call operator. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this call is being recorded. Joining me on the call today will be Dr. Pete Saltzman, Chief Executive Officer of Immune Event. Before we begin, I would like to remind everyone that today's conference call will include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among other things, statements regarding Immunovet's plan to initiate two Phase III clinical trials for beta-climate in TED in the second half of calendar year 2022 with an expected top-line data readout in the first half of calendar year 2025, and it's planned to initiate a Phase III clinical trial in MG by the end of June 2022, with an expected readout in the second half of calendar year 2024. ImmuneVance plans to develop Betaclimab across a broad range of autoimmune indications, the potential efficacy and safety of ImmuneVance product and candidate, Immunovant's expectations regarding the timing, design, and results of its clinical trials, including the timing of future data readouts and the announcement of additional indications, and whether, if approved, beta-climab will be successfully distributed, marketed, and commercialized. All forward-looking statements are based on estimates and assumptions by Immunovant's management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and u...